Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Do we fully understand the economic value of vaccines?

Drummond M, Chevat C, Lothgren M.

Vaccine. 2007 Aug 10;25(32):5945-57. Epub 2007 May 15. Review.

PMID:
17629362
2.

Health economic research on vaccinations and immunisation practices--an introductory primer.

Szucs TD.

Vaccine. 2005 Mar 18;23(17-18):2095-103. Review.

PMID:
15755578
3.

The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P.

Pharmacoeconomics. 2005;23(9):855-74. Review.

PMID:
16153131
4.

[Vaccination: cost-effectiveness ratio].

Swennen B.

Rev Med Brux. 2009 Sep;30(4):451-7. French.

PMID:
19899394
5.

[Vaccination--value for money?].

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Kristiansen IS.

Tidsskr Nor Laegeforen. 2006 Oct 19;126(20):2670-3. Norwegian.

6.

Methodological concerns with economic evaluations of meningococcal vaccines.

Kauf TL.

Pharmacoeconomics. 2010;28(6):449-61. doi: 10.2165/11535280-000000000-00000. Review.

PMID:
20465314
7.

Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M.

Pharmacoeconomics. 2008;26(1):17-32. Review.

PMID:
18088156
8.

Economic evaluations of hepatitis B vaccination for developing countries.

Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ.

Expert Rev Vaccines. 2009 Jul;8(7):907-20. doi: 10.1586/erv.09.53. Review.

PMID:
19538116
9.

Economic aspects of vaccines and immunizations.

Hinman AR.

C R Acad Sci III. 1999 Nov;322(11):989-94. Review.

PMID:
10646095
10.

Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research.

Getsios D, Caro I, El-Hadi W, Caro JJ.

Int J Technol Assess Health Care. 2004 Summer;20(3):280-8. Review.

PMID:
15446757
11.

Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis.

Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS.

Vaccine. 2009 May 21;27(24):3159-64. doi: 10.1016/j.vaccine.2009.03.059. Epub 2009 Apr 9.

PMID:
19446186
12.

Emerging issues in vaccine economics: perspectives from the USA.

Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL.

Expert Rev Vaccines. 2002 Dec;1(4):433-42.

PMID:
12901581
13.
14.

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Kim SY, Goldie SJ.

Pharmacoeconomics. 2008;26(3):191-215. Review.

PMID:
18282015
15.

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.

Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M.

Vaccine. 2009 Aug 6;27(36):4891-904. doi: 10.1016/j.vaccine.2009.05.061. Epub 2009 Jun 9. Review.

PMID:
19520205
16.

New vaccines against otitis media: projected benefits and cost-effectiveness.

O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.

Pediatrics. 2009 Jun;123(6):1452-63. doi: 10.1542/peds.2008-1482.

PMID:
19482754
17.

An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh.

Levin A, Levin C, Kristensen D, Matthias D.

Vaccine. 2007 Sep 28;25(39-40):6945-57. Epub 2007 Jul 25.

PMID:
17707556
18.

Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group.

Newall AT, Kelly H, Harsley S, Scuffham PA.

Pharmacoeconomics. 2009;27(6):439-50. doi: 10.2165/00019053-200927060-00001. Review.

PMID:
19640008
19.

Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.

Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M.

Eur J Public Health. 2008 Jun;18(3):275-82. Epub 2007 Dec 26. Erratum in: Eur J Public Health. 2008 Dec;18(6):693.

20.

Projected cost-effectiveness of new vaccines for adolescents in the United States.

Ortega-Sanchez IR, Lee GM, Jacobs RJ, Prosser LA, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T; Working Group on Leading Economic Issues for New Vaccine for Adolescents.

Pediatrics. 2008 Jan;121 Suppl 1:S63-78. doi: 10.1542/peds.2007-1115H. Review.

PMID:
18174323
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk